Search
avapritinib (Ayvakit)
Indications:
- unresectable or metastatic gastrointestinal stromal tumor (GIST) with a PDGFRA exon 18 mutation, including D842V mutations [1]
* 5=10% of GISTs have a PDGFRA mutation [3]
Dosage:
- 300 mg PO QD on an empty stomach*
* at least 1 hour before or 2 hours after a meal.
Adverse effects:
- > 20%
- edema, nausea, fatigue/asthenia, cognitive impairment, vomiting, decreased appetite, diarrhea, hair color changes, increased lacrimation, abdominal pain, constipation, rash, dizziness
Mechanism of action:
- tyrosine kinase inhibitor, inhibits PDGFRA [3]
Interactions
drug adverse effects of tyrosine kinase inhibitor(s)
General
small inhibitory antineoplastic agent (ib drug)
tyrosine kinase inhibitor
Database Correlations
PUBCHEM cid=118023034
References
- FDA Drug Approvals Jan 10, 2020
FDA approves avapritinib for gastrointestinal stromal tumor with a rare mutation
- Wikipedia: Avapritinib
https://en.wikipedia.org/wiki/Avapritinib
- American Cancer Society. Jan 10, 2020
FDA Approves Ayvakit (Avapritinib) for GIST.
https://www.cancer.org/latest-news/fda-approves-ayvakit-avapritinib-for-gist.html